Nektar Therapeutics (NKTR) Common Equity (2010 - 2026)
Nektar Therapeutics (NKTR) recorded Common Equity of $903.12 million in Q2 2026, compared with -$24.21 million a year earlier and up 56.7% from the prior quarter.
Nektar Therapeutics (NKTR) Common Equity (2010 - 2026) Analysis & Trends
At the end of FY2025, Nektar Therapeutics reported Common Equity of $89.83 million, up 47.9% from FY2024.
- Annual Common Equity has a five-year compound annual growth rate of -39.2% (FY2020 to FY2025).
- Across earlier years, Common Equity came in at $60.74 million in FY2024 (-53.6%), $130.99 million in FY2023 (-64.3%), $366.64 million in FY2022 (-46.0%) and $679.51 million in FY2021 (-36.9%).
- The Q2 2026 figure is the highest quarterly Common Equity since Q2 2021.
- On a year-over-year basis, Common Equity rose in two of the last five quarters, with an average decline of 18.0%.
- Peak year-over-year performance for Common Equity in the last five years was growth of 74.1% in Q3 2025, against a decline of 89.2% in Q1 2025 at the low end.
- Per Business Quant, the preceding three quarters came in at $576.22 million (Q1 2026), $89.83 million (Q4 2025) and $85.09 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 41.98 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 20.25 Bn |
| 10 | Nektar Therapeutics | 2.00 Bn | 227.61 Mn | - | 903.12 Mn |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 903.12 Mn |
| Mar 31, 2026 | 576.22 Mn |
| Dec 31, 2025 | 89.83 Mn |
| Sep 30, 2025 | 85.09 Mn |
| Jun 30, 2025 | -24.21 Mn |
| Mar 31, 2025 | 13.74 Mn |
| Dec 31, 2024 | 60.74 Mn |
| Sep 30, 2024 | 48.88 Mn |
| Jun 30, 2024 | 79.69 Mn |
| Mar 31, 2024 | 126.71 Mn |
| Dec 31, 2023 | 130.99 Mn |
| Sep 30, 2023 | 159.37 Mn |
| Jun 30, 2023 | 196.96 Mn |
| Mar 31, 2023 | 240.87 Mn |
| Dec 31, 2022 | 366.64 Mn |
| Sep 30, 2022 | 412.22 Mn |
| Jun 30, 2022 | 458.73 Mn |
| Mar 31, 2022 | 607.89 Mn |
| Dec 31, 2021 | 679.51 Mn |
| Sep 30, 2021 | 801.54 Mn |
Nektar Therapeutics Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=NKTR&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "NKTR", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=NKTR&period=max&api_key=YOUR_API_KEY");
const data = await res.json();